Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc, announced the launch of the ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) Program. This structured clinical collaboration initiative accelerates aesthetic innovation through practice-led insights and will support the introduction of Obagi saypha MagIQ – the company’s first FDA-approved injectable hyaluronic acid (HA) filler with category-leading features including high useable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile.
“ALOHA reflects our commitment to launching innovation differently and supporting category growth,” said Drew Fine, U.S. General Manager, Professional Channel. “By gathering real-world data across diverse practice settings, we will demonstrate how Obagi saypha MagIQ and Obagi skincare can drive practice success and patient satisfaction. The program’s inclusive design embodies our Aesthetics for All ethos and invites broad industry participation.”
The ALOHA program creates a platform for practices to integrate real-world clinical experience into the product lifecycle. Participants will incorporate Obagi saypha MagIQ into routine treatments and provide structured feedback via standardized surveys from injectors and practice owners. This authentic, practice-driven approach captures insights beyond pivotal trials, informing post-launch education, scientific content, and wider adoption. The program is expected to become the largest real-world evaluation of a newly launched HA injectable.
“We are thrilled to partner with our valued Obagi providers to introduce this MagIQ-al new injectable,” added Mr. Fine. “Practices interested in participating are encouraged to sign up or contact their Obagi representative for more details.”
